Apixaban Study

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Sponsor:
Collaborators:
Pediatric Heart Network
Pfizer
Information provided by (Responsible Party):
Bristol-Myers Squibb